Opinion|Videos|September 4, 2024
Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty
The panel examines the efficacy and safety profiles of gonadotropin-releasing hormone analogue (GnRHa) treatments in managing Central Precocious Puberty.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are long-term efficacy and safety data associated with gonadotropin releasing hormone analogue (GnRHa) treatment?
Advertisement
Related to this article
Researchers discuss how testosterone changes during early puberty may influence depression and anxiety symptoms in girls and implications for pediatricians.
The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
In a meta-analysis of 46 RCTs, behavioral interventions modestly improved HbA1c in youth with T1D; family-focused approaches worked best.
Nationwide Children's experts urge early screening and family-based lifestyle change as youth-onset T2D progresses faster than adult disease.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
How pediatricians can reframe vaccine conversations
2
FDA investigates malignancy risk with SMA gene therapy Zolgensma
3
Distance to surgery linked to complications, longer stays in children
4
Risankizumab shows 52-week efficacy in pediatric psoriasis trial
5